Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with small cell lung cancer (SCLC) that has spread widely through the body (called "extensive-stage"), confirmed by a tissue or cell sample
• People who have not yet received any treatment directed at the whole body (such as chemotherapy) for this cancer
• People whose previous cancer treatment (radiation or chemotherapy) was completed at least 6 months before being diagnosed with extensive-stage SCLC
• People who have at least one measurable area of cancer in the body that has not been previously treated with radiation
• People aged 18 to 70 years old
• People who are generally well enough to carry out everyday activities with no or minimal limitations (confirm with trial site for exact fitness score)
• People who are expected to live for at least 12 weeks
• People whose blood counts, liver, kidney, and clotting function all fall within acceptable ranges as determined by blood tests (confirm with trial site for specific values)
• People who agree to use reliable contraception from the first dose of the study treatment until 6 months after the last dose; women who could become pregnant must have a negative pregnancy test within 7 days before enrolling
• People who have been fully informed about the study and have signed a consent form agreeing to take part

Who may not be able to join:

• People whose lung cancer is confirmed to be a mix of small cell and non-small cell lung cancer types
• People who have previously been treated with immune checkpoint inhibitor drugs, or with irinotecan or similar drugs that work by blocking a specific enzyme (DNA topoisomerase inhibitors)
• People who have taken certain medications that strongly affect how the body processes drugs (strong CYP3A4 inducers within 2 weeks, or strong CYP3A4 or UGT1A1 inhibitors within 1 week before starting the trial drug — confirm with trial site for specific medication examples)
• People who have brain metastases, cancer spread to the lining of the brain or spinal cord, or spinal cord compression that is causing symptoms
• People who have a blood or bone marrow disorder such as lymphoma, leukaemia, multiple myeloma, aplastic anaemia, or myelodysplastic syndrome
• People who have significant fluid build-up around the heart, lungs, or abdomen that cannot be managed with drainage or other treatments
• People who have an active, known, or suspected disease in which the immune system attacks the body (autoimmune disease)
• People who have used corticosteroids above a low threshold dose, or other medicines that suppress the immune system, within 14 days before starting the trial drug
• People who have received a live vaccine, or plan to receive one, within 4 weeks before starting the trial drug
• People who have a lung condition involving scarring or inflammation of lung tissue, or active pneumonia causing symptoms, or severely reduced lung function
• People who have active tuberculosis, or had active tuberculosis within the past 48 weeks
• People who still have significant side effects from previous cancer treatments that have not settled down sufficiently before starting the trial drug
• People who had a minor surgical procedure (including insertion of a catheter) within 48 hours before starting the trial drug
• People who have uncontrolled heart or blood vessel problems
• People who are known to be allergic to the trial drug or any of its ingredients
• People who have had another cancer within the past 5 years, except for certain treated skin cancers or very early-stage cancers that were fully treated (confirm with trial site)
• People with a history of psychiatric disorders, alcohol misuse, drug misuse, or substance misuse
• People with certain active or chronic viral infections including hepatitis B (with elevated virus levels), hepatitis C, or HIV/AIDS
• People who have taken part in another clinical trial or received another experimental drug within 4 weeks before signing the consent form
• People who have previously had a bone marrow transplant or organ transplant from another person
• People who are considered ineligible for any other reason as determined by the treating doctor at the trial site

Important: Always verify eligibility with the trial site directly before applying.